Literature DB >> 12103339

Melan-A/MART-1-specific CD8 T cells: from thymus to tumor.

Mikaël J Pittet1, Alfred Zippelius, Danila Valmori, Daniel E Speiser, Jean-Charles Cerottini, Pedro Romero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12103339     DOI： 10.1016/s1471-4906(02)02244-5

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


× No keyword cloud information.
  14 in total

1.  Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers.

Authors:  Brigitte Gückel; Christine Rentzsch; Maria-Dorothea Nastke; Alexander Marmé; Ines Gruber; Stefan Stevanović; Simone Kayser; Diethelm Wallwiener
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-22       Impact factor: 4.553

2.  Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.

Authors:  David K Cole; Fang Yuan; Pierre J Rizkallah; John J Miles; Emma Gostick; David A Price; George F Gao; Bent K Jakobsen; Andrew K Sewell
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

3.  Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Authors:  Ekaterina Doubrovina; Taissia Carpenter; Dmitry Pankov; Annamalai Selvakumar; Aisha Hasan; Richard J O'Reilly
Journal:  Blood       Date:  2012-05-23       Impact factor: 22.113

4.  IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells.

Authors:  Osamu Imataki; Sascha Ansén; Makito Tanaka; Marcus O Butler; Alla Berezovskaya; Matthew I Milstein; Kiyotaka Kuzushima; Lee M Nadler; Naoto Hirano
Journal:  J Immunol       Date:  2012-01-11       Impact factor: 5.422

5.  PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.

Authors:  Julien Fourcade; Pavol Kudela; Zhaojun Sun; Hongmei Shen; Stephanie R Land; Diana Lenzner; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; Soldano Ferrone; John M Kirkwood; Hassane M Zarour
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

6.  Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma.

Authors:  Robert Suriano; Shilpi Rajoria; Andrea L George; Jan Geliebter; Raj K Tiwari; Marc Wallack
Journal:  Mol Clin Oncol       Date:  2013-03-20

7.  The immune response to melanoma is limited by thymic selection of self-antigens.

Authors:  Ulrike Träger; Sophie Sierro; Gordana Djordjevic; Basma Bouzo; Shivani Khandwala; Antonella Meloni; Monika Mortensen; Anna Katharina Simon
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

8.  Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines.

Authors:  Robert Suriano; Shilpi Rajoria; Andrea L George; Jan Geliebter; Marc Wallack; Raj K Tiwari
Journal:  J Cancer       Date:  2013-06-19       Impact factor: 4.207

9.  Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes.

Authors:  Scott M Lieberman; Anne M Evans; Bingye Han; Toshiyuki Takaki; Yuliya Vinnitskaya; Jennifer A Caldwell; David V Serreze; Jeffrey Shabanowitz; Donald F Hunt; Stanley G Nathenson; Pere Santamaria; Teresa P DiLorenzo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-18       Impact factor: 12.779

10.  Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope.

Authors:  Keri L Schaubert; David A Price; Nicole Frahm; Jinzhu Li; Hwee L Ng; Aviva Joseph; Elyse Paul; Biswanath Majumder; Velpandi Ayyavoo; Emma Gostick; Sharon Adams; Francesco M Marincola; Andrew K Sewell; Marcus Altfeld; Jason M Brenchley; Daniel C Douek; Otto O Yang; Christian Brander; Harris Goldstein; June Kan-Mitchell
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.